Immix Biopharma reports strong NEXICART-2 response data

• Immix Biopharma reported an 89% complete response rate in the interim analysis of its Phase 2 NEXICART-2 trial of NXC-201 in relapsed or refractory AL amyloidosis.
• An independent review committee confirmed complete responses in 40 of 45 treated patients.
• The company expects a final trial readout and potential biologics license application submission in mid-2027.

Immix Biopharma (NASDAQ:IMMX) reported interim results from its Phase 2 NEXICART-2 clinical trial evaluating NXC-201 in patients with relapsed or refractory AL amyloidosis.

An independent review committee identified complete responses in 40 of 45 patients treated with NXC-201, representing an 89% complete response rate across the study population.

Among 25 newly reported patients included in the update, 21 achieved complete response.

The remaining four patients were negative for minimum residual disease (MRD), a bone-marrow measurement used to assess disease burden, but have not yet reached complete response.

Immix said the MRD-negative results among these four patients could potentially increase the eventual complete response rate to as high as 98%, or 44 out of 45 patients, if those responses convert to complete responses.

The company reported that no relapses have been observed among patients achieving complete response or MRD negativity.

Immix also said no cases of neurotoxicity or enterocolitis have been observed to date.

Immix plans to provide a final NEXICART-2 data readout and submit a biologics license application (BLA) for NXC-201 in mid-2027.